Visual Outcomes Of Bilateral Implantation Of An Enhanced Monofocal Intraocular Lens Targeted For Mini-Monovision

To evaluate the clinical and visual performance of an enhanced monofocal intraocular lens (IOL) with a mini-monovision of -0.75 D.

Single-center, prospective clinical trial at the Department of Ophthalmology, Medical University of Vienna, Austria.

This prospective study included 50 patients with bilateral cataract and a corneal astigmatism <0.75D. Each patient received bilateral implantation of the enhanced monofocal Vivinex Impress IOL (HOYA Surgical Optics). The dominant eye was targeted for emmetropia, while the non-dominant eye was targeted for -0.75D. Two to four months postoperatively, uncorrected binocular distance, intermediate, and near visual acuity were evaluated, along with the defocus curve, subjective photic phenomena, patient satisfaction, and stereopsis.

Mean binocular uncorrected distance visual acuity (UDVA), uncorrected intermediate visual acuity (UIVA) at 80 cm and 66 cm, and uncorrected near visual acuity (UNVA) at 40 cm were 0.04±0.10, 0.04±0.12, 0.03±0.10, and 0.16±0.08 logMAR, respectively. Binocular defocus curves in the initial patient cohort (n = 14) demonstrated a depth of field, defined as the range of defocus where visual acuity remains better than 0.2 logMAR, of -1.84D.

Enhanced monofocal IOLs can provide an extended depth of field and excellent intermediate visual acuity while maintaining high visual quality and minimal side effects, especially when targeted for mini-monovision.